In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Intellia Therapeutics (NTLA). The company’s shares closed last Thursday at $28.48.
According to TipRanks.com, Olson is a 2-star analyst with an average return of 0.6% and a 47.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Axovant Gene Therapies, and Frequency Therapeutics.
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $35.05, a 24.1% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Hold rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
Based on Intellia Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $16.26 million and GAAP net loss of $32.39 million. In comparison, last year the company earned revenue of $11.12 million and had a GAAP net loss of $25.68 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
